{"classes":[{"categories":[{"measurements":[{"comment":"A confidence interval cannot be computed when the rate is zero, i.e. when there are zero events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"A confidence interval cannot be computed when the rate is zero, i.e. when there are zero events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"groupId":"OG002","lowerLimit":"0.4","upperLimit":"28.7","value":"7.1"},{"groupId":"OG003","lowerLimit":"0.9","upperLimit":"15.7","value":"5.3"},{"groupId":"OG004","lowerLimit":"1","upperLimit":"17.9","value":"6.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"33"}],"units":"Participants"}],"description":"Regional nodal progression is defined as appearance after protocol therapy of measurable tumor within lymph nodes along the natural lymphatic drainage typical for the location of the treated primary disease only with dimension of at least 1.0 cm on imaging studies (preferably CT scans) within the lung, bronchial hilum, or the mediastinum. Regional nodal progression was assessed using the cumulative incidence method to estimate the 2-year failure rate. Arms were not compared/tested.","dispersionType":"95% Confidence Interval","groups":[{"description":"SBRT delivered in 5 fractions of 10.0 Gy/fraction over 1.5 to 2 weeks for a total of 50.0 Gy","id":"OG000","title":"Level 5: 10.0 Gy/FX"},{"description":"SBRT delivered in 5 fractions of 10.5 Gy/fraction over 1.5 to 2 weeks for a total of 52.5 Gy","id":"OG001","title":"Level 6: 10.5 Gy/FX"},{"description":"SBRT delivered in 5 fractions of 11.0 Gy/fraction over 1.5 to 2 weeks for a total of 55.0 Gy","id":"OG002","title":"Level 7: 11.0 Gy/FX"},{"description":"SBRT 57.5 Gy\n\nSBRT delivered in 5 fractions of 11.5 Gy/fraction over 1.5 to 2 weeks for a total of 57.5 Gy","id":"OG003","title":"Level 8: 11.5 Gy/FX"},{"description":"SBRT 60.0 Gy\n\nSBRT delivered in 5 fractions of 12.0 Gy/fraction over 1.5 to 2 weeks for a total of 60.0 Gy","id":"OG004","title":"Level 9: 12.0 Gy/FX"}],"paramType":"NUMBER","populationDescription":"All eligible patients who started study treatment","reportingStatus":"POSTED","timeFrame":"From randomization to date of death, regional failure or last follow-up. Analysis occurs after all patients have been potentially followed for 24 months, approximately 7.5 years from the start of the study.","title":"Nodal Progression","type":"SECONDARY","unitOfMeasure":"percentage of patients"}